Home
Clinical Trials
Progression of Early Subclini...

Progression of Early Subclinical Atherosclerosis

Last Updated: 2021-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

4184 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-14

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of atheroma plaques and to the presence of genetic, epigenetic, metabolomic, and environmental factors, including dietary habits, physical activity, biorhythms, psychosocial characteristics, and exposure to environmental pollutants

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetical, Anthropometrical and Biochemical Factors Influencing High Risk Subclinical Atherosclerosis

NCT02487615

Primary Prevention

COMPLETED

Progression of Sub-Clinical Atherosclerosis

NCT00241787

Atherosclerosis Cardiovascular Diseases Heart Diseases +1 more

COMPLETED

Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease

NCT01041729

Peripheral Arterial Disease

COMPLETED PHASE4

Early Atherosclerosis Change in Two Clinical Trials

NCT00005696

Cardiovascular Diseases Heart Diseases Carotid Artery Diseases +2 more

COMPLETED

EARly Prevention of aTHeroma Progression

NCT02105623

Coronary Arteriosclerosis

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atherosclerosis is the most common cardiovascular disease and accounts for the greatest number of deaths. Atherosclerotic disease starts at an early age and follows a subclinical course for decades, becoming apparent in the fifth or sixth decades of life in men and approximately 10 years later in women. Its main clinical signs include myocardial infarction, angina pectoris, sudden death, or stroke. Disease occurrence and progression are conditioned by the presence of the so-called risk factors: smoking, dyslipidemia, hypertension, and diabetes, among others. From these factors, a number of equations have been developed for predicting the risk of an individual to suffer the disease, in order to apply adequate prevention measures such as lifestyle changes or drug treatment. However, despite the proven efficacy of such interventions, cardiovascular prevention has many limitations due to three significant problems:

1. The ability to predict risk from current equations is very limited because other genetic or environmental factors that may influence the course of disease are still unknown.
2. The ability for early prediction of cardiovascular risk from current equations is even more limited in individuals under 55 years of age.
3. Atherosclerotic disease is diagnosed too late, usually when the condition is very advanced and lesions are already irreversible, or when it has caused clinical signs or events in organs or territories vascularized by the diseased arteries. Clinical procedures currently used for detection of myocardial ischemia are however poorly sensitive and specific in the asymptomatic general population.

Technological advances made in the past decade in both laboratory tests and medical imaging have opened up new expectations for detection and treatment of atherosclerotic disease. Current research is focused on two aspects:

1. To improve the ability to predict the disease by incorporating risk factors obtained from the laboratory such as C-reactive protein, homocysteine, fibrinogen, myeloperoxidase, or lipoprotein-associated phospholipase A2. At the same time, development of genetics and the new so-called "omics" techniques allows for exploring the genetic variability of individuals and its contribution to development of the disease and its complications. Such technologies include genomics, epigenetics, transcriptomics, proteomics, and metabolomics.
2. To detect the disease at an early stage using the advanced imaging techniques, which may be used with no or minimal risks in large population groups. Use of magnetic resonance imaging (MRI) with and without contrast, computed tomography (CT), and positron emission tomography (PET) allows not only for identifying subclinical lesions, but also for studying the mechanisms of disease and for monitoring its course.

Very few population studies making combined use of some of these procedures are available. The actual potential of this approach and the impact it may have on early diagnosis of subclinical atherosclerosis, its progression, and its relationship to risk factors have not been assessed to date.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Employees of the Banco de Santander Group
* Age between 40-54 years.

Exclusion Criteria

* Myocardial Infarction
* Angina pectoris
* Stroke, either transient or with sequelae
* Peripheral vascular disease
* Prior angioplasty or heart surgery
* Atrial fibrillation
* Other heart diseases

Subjects with the following conditions will also be excluded:

* Pregnancy
* Active treatment for any cancer
* Morbid obesity (BMI ≥40)
* Renal failure with creatinine clearance \<60 mL/min, as estimated by the Cockcroft and Gault formula
* Any disease that decreases life expectation to ≤6 years
* Pacemaker, implantable automatic defibrillator, or any implanted device that contraindicates MRI
* A chest CT in the previous year

Minimum Eligible Age

40 Years

Maximum Eligible Age

54 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR